Longboard Pharmaceuticals, Inc., (LBPH) News

Longboard Pharmaceuticals, Inc., (LBPH): $18.80

0.14 (-0.74%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add LBPH to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#279 of 357

in industry

Filter LBPH News Items

LBPH News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest LBPH News From Around the Web

Below are the latest news stories about LONGBOARD PHARMACEUTICALS INC that investors may wish to consider to help them evaluate LBPH as an investment opportunity.

Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers

LA JOLLA, Calif., November 29, 2023--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the initiation of a Phase 1 randomized, double-blind, placebo-controlled, SAD clinical study of LP659. LP659 is an oral, centrally acting, next-generation sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator in development for the potential treatment of rare neu

Yahoo | November 29, 2023

Down -25.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Longboard Pharmaceuticals, Inc. (LBPH)

Longboard Pharmaceuticals, Inc. (LBPH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Yahoo | November 24, 2023

Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community

LA JOLLA, Calif., November 21, 2023--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present data for LP352, a novel, highly selective investigational treatment in development for seizures associated with a range of Developmental and Epileptic Encephalopathies (DEEs), in poster sessions at the 2023 AES Annual Meeting. Longboard will also host a

Yahoo | November 21, 2023

Farallon Capital: A Global and Diversified Hedge Fund and its Top Stock Picks

In this article, we discuss Farallon Capital: a global and diversified hedge fund and its top stock picks. If you want to skip our detailed analysis of these stocks, go directly to the Top 5 Stock Picks of Farallon Capital. Risk arbitrage or merger arbitrage is one of the most popular strategies that hedge funds […]

Yahoo | November 13, 2023

Wall Street Analysts Believe Longboard Pharmaceuticals, Inc. (LBPH) Could Rally 262.45%: Here's is How to Trade

The consensus price target hints at a 262.5% upside potential for Longboard Pharmaceuticals, Inc. (LBPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | November 8, 2023

Longboard Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

LA JOLLA, Calif., November 03, 2023--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to one new employee. The Compensation Committee of the Board of Directors of Longboard approved the grant of non-qualified stock options to purchase an aggregate of 58,520 shares of its common stock (the "Common Stock") as inducements material

Yahoo | November 3, 2023

Longboard Pharmaceuticals Inc (LBPH) Reports Q3 2023 Financial Results

Company's cash and cash equivalents stand at $56 million, R&D expenses increase by 12% YoY

Yahoo | November 2, 2023

Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results

LA JOLLA, Calif., November 02, 2023--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2023.

Yahoo | November 2, 2023

Longboard Pharmaceuticals to Present at Three Upcoming Investor Conferences in November

LA JOLLA, Calif., November 01, 2023--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior management team will present at three upcoming investor conferences in November.

Yahoo | November 1, 2023

We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | October 19, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!